Pfizer (NYSE:PFE) Stock Price Up 1.3% – Time to Buy?

Pfizer Inc. (NYSE:PFE) shares traded up 1.3% on Tuesday . The stock traded as high as $24.35 and last traded at $24.0370. 43,867,471 shares traded hands during trading, an increase of 2% from the average daily volume of 42,799,309 shares. The stock had previously closed at $23.72.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported fresh updates from its early-stage pipeline, including a Phase 1 bioavailability study and the MUST observational study in multiple myeloma, which may reinforce confidence in the company’s long-term drug development efforts. Pfizer Refines Early-Stage Drug Formulations With New Phase 1 Bioavailability Study
• Positive Sentiment: Pfizer also benefited from a biotech sector boost after AstraZeneca and Ionis suffered a late-stage trial setback, which lifted shares of some rivals including Pfizer as investors rotated toward peers with comparatively steadier pipelines. Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/ Ionis
• Positive Sentiment: Separate commentary highlighted Pfizer’s unusually high dividend yield near 7%, which may continue to attract income-focused investors even though sentiment remains cautious. ‘It Kills Me to Say That’: Cramer Won’t Recommend Pfizer, Even With Its 7% Dividend

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. Citigroup increased their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a report on Wednesday, April 29th. Finally, JPMorgan Chase & Co. reduced their price target on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.56.

Pfizer Stock Performance

The business has a 50-day moving average of $25.46 and a 200 day moving average of $26.20. The company has a market cap of $137.84 billion, a PE ratio of 18.46 and a beta of 0.35. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the previous year, the company posted $0.92 EPS. The firm’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock worth $13,479,520,000 after purchasing an additional 7,031,162 shares during the period. State Street Corp boosted its stake in shares of Pfizer by 0.5% during the fourth quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock valued at $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC increased its holdings in Pfizer by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after buying an additional 1,184,728 shares during the period. Morgan Stanley raised its stake in Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares in the last quarter. Finally, Norges Bank bought a new stake in Pfizer during the 4th quarter valued at $1,830,986,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.